Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant Multi-Link Pixel

This article was originally published in The Gray Sheet

Executive Summary

First human implant of the coronary stent system for small vessels is performed July 11 at Sacred Heart Medical Center in Eugene, Oregon. The stent is intended to treat threatened abrupt closures of first-time or recurring blockages in small vessels with diameters of less than 3.0 mm. Separately, the firm has launched a multi-center safety and feasibility study to evaluate the AccuNet embolic protection system to reduce stroke during minimally invasive carotid artery stenting procedures. Guidant had submitted an IDE for the 50-patient study in May (1"The Gray Sheet" May 29, p. 3)

You may also be interested in...



HCFA Conditional Coverage For Clinical Trials Unlikely In Near-Term

The Health Care Financing Administration will not provide "conditional coverage" under Medicare for the ongoing REMATCH trial evaluating congestive heart failure treatment using Thermo Cardiosystems, Inc.'s HeartMate left ventricular assist device.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel